Docetaxel-incorporated calcium phosphate nanoparticles for lung cancer treatment:synthesis, characte

来源 :第九届全国无机化学学术会议 | 被引量 : 0次 | 上传用户:fengyunwoaihui
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  Lung cancer is a disease characterized by uncontrolled cell growth in tissues of the lung.As an antineoplastic agent,docetaxel(DTX)is considered as one of the most effective drugs in chemotherapy for treating many cancers,including lung cancer.[1] In this work,we devised a simple method for incorporating DTX into calcium phosphate nanoparticles(CaP NPs).
其他文献
A great many Schiff base complexes with transition metals have been confirmed possessing biological and pharmaceutical activities,such as anticancer,antitumor and antioxidative activities as well as t
Bio-inspired particles,mimicking certain biochemical and physical attributes of biological cells,have attracted considerable attention because of their cell-like biological functions,including oxygen
Great efforts are being made to develop new-type “non-classical” platinum-containing complexes with better efficiency for exploring cancer therapy to circumvent the drawbacks what platinum complexes i
Alzheimers disease(AD)is the most common form of dementia.Amyloid β(Aβ),a peptide of 40 or 42 amino acids,plays a key role in AD pathology.The aggregation of Aβ is one of the neuropathological hallmar
A novel 1D supramolecular Cd(Ⅱ)complex has been synthesized and characterized as [(CdL2·4H2O)·4H2O](1)using 4-(acetylamino)benzoate(HL).
合成了一种新的L-组氨酸水杨醛希夫碱和邻菲咯啉混配体镍(Ⅱ)配合物,[Ni(Sal-L-His)(Phen)]H2O](Sal-L-His为水杨醛与L-组氨酸形成的希夫碱,Phen=1,10-邻菲咯啉),利用红外光谱进行了表征。
Photodynamic therapy(PDT)has gained extensive attention as an emerging treatment modality.To date,upconversion nanoparticles conjugated with photosensitizers(UCNP-PS)has become an effective nano-platf
Metal complexes have been widely studied as potent proteasome inhibitors.The 20S proteasome,the main component of the ubiquitin proteasome system,has been one of the excellent targets in anticancer dr
Two asymmetric schiff–base ligands L1,L2(L1= N-Furan-2-ylmethylene-N-{2-[(4-methoxy-benzylidene)-amino]-ethyl}-1,2-diamine,L2 = 4-Brome-2-[(2-{2-[Furan-2-ylmethylene)-amino]-ethylamino}-methyl]-phenol
硼中子俘获(BNCT)治疗癌症是利用中子束和10B发生原子核反应,释放高能粒子杀死癌细胞,是一种二元治疗模式[1,2]。目前临床使用硼携带剂都属于化合物型药物,缺乏对病灶部位的可控靶向聚集[3],含10B的纳米颗粒,特别是Fe2B磁性纳米颗粒,一方面具有磁性纳米材料的可控性,易修饰性,可以修饰各种生物靶向分子,另一方面具有较高的硼含量,是一种潜在的BNCT硼携带药物。